



**Clinico-Pathological Features of Differentiated
Thyroid Cancer And Their Impacts
on Prognosis**

Thesis

Submitted for Partial Fulfillment of Master Degree
in Clinical Oncology and Nuclear Medicine

By

Ali Layth Ahmed

M.B.B.C.H.

Under supervision of

Dr. Khaled Abdel Karim Mohamed

Professor of Clinical Oncology and Nuclear medicine
Faculty of Medicine – Ain Shams University

Dr. Khaled Nagib Abdelhakim

Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

Dr. Mohamed Reda Kelany

Lecturer of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

Department of Clinical Oncology and Nuclear Medicine
Ain Shams University

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

First and forever, thanks to **Allah**, Almighty for giving me the strength and faith to complete my thesis and for everything else.

I would like to express my deepest gratitude and appreciation to **Dr. Khaled Abdel Karim Mohamed**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine – Ain Shams University, for his kindness, over available, untiring supervision, helpful criticism and support during the whole work. I really have the honor to complete this work under his supervision.

My extreme thanks and gratefulness to **Dr. Khaled Nagib Abdelhakim**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine – Ain Shams University, I'm much grateful for his patience and strict supervision and revision of this work. His valuable advice helped me a lot to pass many difficulties.

No words can express my gratitude to **Dr. Mohamed Reda Kelany**, Lecturer of Clinical Oncology and Nuclear Medicine, Faculty of Medicine – Ain Shams University, for the efforts and time he has devoted to accomplish this work.

Last but not least, I would like to thank all members of my family, specially my **Parents** and my **Wife**, for their care and support.

 *Ali Layth Ahmed*

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables	iii
List of Figures	v
Introduction	1
Aim of the Work	3
Review of Literature	
Epidemiology of Thyroid Cancer	4
Pathology	7
Risk assessment & Prognosis	17
Diagnosis	26
Follow-up of DTC patients	53
Subjects and Methods	66
Results	69
Discussion	91
Summary & Conclusion	106
Recommendations	108
References	109
Arabic Summary	—

List of Abbreviations

<i>Abbrev.</i>	<i>Full-term</i>
AACE	: American Association of Clinical Endocrinologists
AGES	: Age, grade of tumor, extent, size
AJCC	: American Joint Committee on Cancer
AMES	: Age, metastases, extent, size
ATA	: American Thyroid Association
ATC	: Anaplastic thyroid carcinoma
CT	: Computed tomography
DTC	: Differentiated thyroid carcinoma
DxWBS	: Diagnostic whole body scan
EBRT	: External Beam Radiotherapy
EORTC	: European Organization for Research on Treatment of Cancer
ETA	: European Thyroid Association
FDG-PET	: Fluorodeoxyglucose positron emission tomography
FNAB	: Fine needle aspiration biopsy
FSH	: Follicle stimulating hormone
FTC	: Follicular thyroid carcinomas
FV-PTC	: Follicular variant of PTC
Gbq	: Gigabecquere
I¹²³	: Iodine 123
I¹³¹	: Iodine 131
IHC	: Immunohistochemistry
LAP	: Lymphadenopathy

MACIS	: Metastases, age, completeness of resection, invasion, size
Mci	: Millicuri
MNG	: Multinodular goiter
MRI	: Magnetic resonance imaging
MSKCC	: Memorial Sloan-Kettering cancer center
MTC	: Medullary thyroid carcinomas
NCCN	: National Comprehensive Cancer Network
OS	: Overall survival
PFS	: Progression-free survival
PTC	: Papillary thyroid carcinomas
Ptmc	: Papillary Thyroid Microcarcinomas
RAI	: Radioactive iodine
RET/PTC	: Rearranged in Transformation/Papillary Thyroid Carcinoma
rhTSH	: Recombinant human TSH
RRA	: Radioiodine remnant ablation
RxWBS	: Post-therapeutic I131 whole body scan
STN	: Solitary thyroid nodule
Tc99m	: Technetium
Tg	: Thyroglobulin
TgAb	: Thyroglobulin Antibody
TSH	: Thyroid Stimulating Hormone
U/S	: Ultrasound
UICC	: Union for International Cancer Control
WBS	: Whole-body scan
WHO	: World Health Organization

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Classification of Malignant Thyroid Tumors	8
Table (2):	AJCC TNM staging for thyroid carcinoma	18
Table (3):	AJCC staging groups for thyroid carcinoma	19
Table (4):	Comparison of Different Prognostic Classification Systems in Differentiated Thyroid Carcinoma	19
Table (5):	Risk stratification variables influencing differentiated thyroid cancer recurrence and cancer death	20
Table (6):	Risk stratification for recurrence risk in thyroid carcinoma according to the ETA and ATA guidelines	22
Table (7):	Increased risk of malignancy in thyroid nodule on history and physical exam	27
Table (8):	Sonographic Features predicting attitude of thyroid nodule	29
Table (9):	The Bethesda system for reporting thyroid cytopathology	34
Table (10):	Comparison of indications on RAI remnant ablation for DTC among different guidelines	40

Table (11):	Demographic data distribution of the study group.....	69
Table (12):	Histopathology distribution of the study group.	71
Table (13):	Clinical history distribution of the study group.	73
Table (14):	Investigations and imaging methods distribution of the study group.	75
Table (15):	Treatment outcomes of the study group.	79
Table (16):	Comparison between relapsed and not relapsed patients according to demographic data.....	80
Table (17):	Comparison between relapsed and not relapsed patients according to histopathology.	83
Table (18):	Different doses of RAI131 received by patients and their relapse status.....	85
Table (19):	Comparison between relapsed and not relapsed according to RAI ablation dose mCi.....	85
Table (20):	Comparison between relapsed and not relapsed according to investigations.....	86
Table (21):	Comparison between relapsed and not relapsed patients according to imaging methods.	88
Table (22):	Logistic regression of factors affecting relapsed and not relapsed.	89

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Incidence rate of thyroid cancer between male and female in worldwide	5
Figure (2):	Papillary carcinoma of the thyroid, microscopic	10
Figure (3):	Follicular carcinoma of the thyroid.	15
Figure (4):	Marked hypoechogenicity of a thyroid nodule.	30
Figure (5):	A prominent, “cold,” or hypofunctioning area in the midaspect of the right lobe is demonstrated	32
Figure (6):	Detection of metastatic lymph nodes on RxWBS, not on DxWBS.	46
Figure (7):	18 FDG PET/CT for 72-y-old woman with papillary thyroid cancer underwent 131I ablation	62
Figure (8):	Pie chart of stage distribution of the study group.	72
Figure (9):	Bar chart investigations and imaging methods distribution of the study group.	76
Figure (10):	Pie chart response to treatment distribution of the study group.	77
Figure (11):	Pie chart type of relapse distribution of the study group.	78
Figure (12):	Bar chart between relapsed and not relapsed according to demographic data.	81
Figure (13):	Bar chart between relapsed and not relapsed according to stage, grade and capsular invasion.	84

Figure (14): Bar chart between relapsed and not relapsed patients according to TG rise on follow up and post op TG (ng/ml).87

Figure (15): Bar chart between relapsed and not relapsed according to imaging methods.88

Figure (16): Progression free survival using Kaplan-Meier Survival analysis of the study group.90

Introduction

Thyroid cancer is the most common endocrine malignancy and presenting the fifth most common cancer among women and incidence has been increased in the last three decades ⁽¹⁾.

Differentiated thyroid cancer (DTC) is the most common type of thyroid cancer, accounting for >90% of all cases and usually has an excellent prognosis .DTC include two subtypes, papillary thyroid cancer (PTC) which is the commonest and follicular thyroid cancer (FTC) ⁽²⁾.

DTC is usually asymptomatic for long periods of time. However solitary thyroid nodule is the common presentation, where thyroid cancer could be found in 7%–15% of these nodules, depending on age, sex, radiation exposure history, family history, and other factors ⁽³⁾.

The thyroid stimulating hormone (TSH) level, ultrasound results and clinical features are used to determine whether is it necessary to do fine-needle aspiration (FNA) of the nodule or whether there is a low risk of malignancy, where FNA consider the procedure of choice for evaluating suspicious thyroid nodule ⁽⁴⁾.

Surgery is the mainstay of the treatment of DTC patients with or without radioactive iodine therapy and lifelong TSH suppression ⁽⁵⁾.

Histological type of carcinoma and the extent of local and regional spread determine the recommended extent of primary surgical resection of DTC, in contrast, secondary factors that could affect the individual prognosis, such as age of the patient or the molecular status of the tumor play no role in the current guidelines' recommendations for the surgical treatment of DTC ⁽⁶⁾.

Disparity can be found in the guidelines in their recommendations about adjuvant radioactive iodine therapy for low-risk thyroid carcinomas, however ⁽⁵⁾, it is clearly indicated for the treatment of metastases that take up iodine and are not amenable to curative resection like in lungs and bone metastases ⁽⁷⁾.

Despite the fact that many advances were achieved in the diagnosis and therapy of both thyroid nodules and DTC, but clinical controversy still exists in many areas. A long history of insufficient peer reviewed research funding for high quality clinical trials in the field of thyroid neoplasia may be an important contributing factor to existing clinical uncertainties ⁽⁸⁾.

Aim of the Work

This is a retrospective study which aims to analyze the clinical and pathological features of DTC and their impacts on the prognosis for patients with differentiated thyroid cancer who attended the Department of Clinical Oncology and Nuclear medicine in Ain Shams University Hospital between the years (2011-2016).

Chapter One

Epidemiology of Thyroid Cancer

Incidence:

Thyroid cancer is the most common endocrine malignancy, from all malignant tumors it forms about 1-2%. In recent decades the increment in its incidence has been reported world widely and many studies have confirmed this rising in its incidence in Europe, Canada and the United states of America ^(9,10).

The incidence of thyroid cancer is about three to four times higher among females than males over the world, ranking the sixth most common malignancy diagnosed in women. Although thyroid cancer may occur at any age, However it is rare in childhood, tumors are usually diagnosed during third to sixth decade of life ⁽¹¹⁾.

In United states Approximately 60,220 new cases of thyroid cancer are diagnosed annually with female to male ratio about 3:1 ⁽¹²⁾.

In Europe thyroid cancer is the 18th most common cancer, with around 53,000 new cases diagnosed in 2012 (2% of the total) ⁽¹³⁾.

In Egypt, thyroid cancer represents about 1.5% of all cancers and constitutes about 30% of endocrine malignancies. The rate among Egyptian females is 0.0027% with female to male ratio is less than 3:1 (8).

Generally Thyroid cancer incidence rates are highest in Northern America and lowest in Western and Middle Africa, but this partly reflects varying data quality worldwide (14). Figure (1) below showing incidence rate of thyroid cancer according to gender world widely.




Figure (1): Incidence rate of thyroid cancer between male and female in worldwide (15)

Risk factors:

- Ionizing radiation:

The most established risk factor for Thyroid cancer is the exposure to ionizing Radiation during infancy or early childhood, where the ability to concentrate iodine and the